GW Pharmaceuticals PLC is a biopharmaceutical company focused on the development and commercialization of novel therapeutics from its proprietary cannabinoid product platform. Currently, the company’s primary product offering is Sativex®, which is approved for the treatment of spasticity related to multiple sclerosis in 27 countries outside of the United States. To increase market share, the company has entered into licensing agreements for Sativex® with major industry players, including Bayer Healthcare in the UK and Canada and Almirall in Europe and Mexico, providing a platform for enhanced returns moving forward. In addition to approval for spasticity treatment, Sativex® is also in Phase III clinical development for the treatment of cancer pain, which is the lead indication for the US market.
Since 2007, GW has established a world leading position in cannabinoid science development through a global cannabinoid research agreement with Japanese pharmaceutical giant Otsuka. Under this collaboration, the company is primarily researching novel cannabinoid treatments for Central Nervous System disorders and oncology.
In addition to Sativex®, GW is currently developing Epidiolex®, an investigational drug designed to treat one of the most common neurological disorders in children, pediatric epilepsy. When completed, Epidiolex® should become the leading treatment for the disorder, providing a better solution to an underserved market of nearly 250,000 patients throughout the United States and Europe.
In an effort to prepare for future growth, GW recently announced the relocation of its Chief Executive Officer to its new United States operations center. A local presence within the US market could provide GW with the opportunity to realize substantial growth as the company’s products approach their final stages of clinical development in the United States. Likewise, the company is continuing to expand its UK manufacturing and R&D operations in preparation for future commercialization of its most advanced drug candidates.
“As Epidiolex® nears its final stages of clinical development and as GW prepares for future U.S. launch, the time is right to start building our in-house U.S. commercial infrastructure,” stated Dr. Geoffrey Guy, Chairman of GW.
With continuing progress towards pivotal Phase III advanced cancer pain results, an impending launch of Sativex® in the US and the advancement of its proprietary pipeline of cannabinoid orphan drug opportunities, GW is in a strong position to provide improved shareholder returns in the coming months. Moving forward, it’s an opportune time for prospective shareholders to consider investing in this expanding company.
For more information, visit www.gwpharm.com
